Hepatitis C News

Janssen announced it will discontinue further development of the investigational hepatitis C regimen JNJ-4178, a direct-acting antiviral combination of AL-335, odalasvir and the company’s simeprevir regimen Olysio, according to a press release.

Women of child-bearing age with hepatitis C showed early signs of menopause, putting them at greater risk for infertility, gestational diabetes and miscarriage, according to a recently published study. Sustained virologic response positively impacted these outcomes.

Most people who inject drugs were not aware of currently available, highly effective hepatitis C treatments, according results of a national survey in Scotland presented at the International Symposium on Hepatitis Care in Substance Users.

Adult injection drug users aged 30 years or younger are both at the highest risk for acquiring hepatitis C and transmitting HCV, according to a presentation at the International Symposium on Hepatitis Care in Substance Users.

Sofosbuvir-based direct-acting antiviral therapy was safe and effective for patients with chronic kidney disease and hepatitis C, particularly for patients with advanced chronic kidney disease, according to a recently published study.

Women who inject drugs are about 39% more likely to become infected with hepatitis C virus than men who inject drugs, research suggests.

Experts estimate that the hepatitis C market in the Asia-Pacific region — including India, China, Australia, South Korea and Japan — will grow from $5.3 in 2016 to $8.3 billion in 2023, according to a press release from GBI Research.

Cost-effectiveness research and analyses of hepatitis C treatment thus far lacks patient engagement, according to a recently published literature review. These patients face a variety of negative physical, social and psychological effects that are not represented in studies focused on payer outcomes.

Recently, the nation of Georgia and the Cherokee Nation in Oklahoma have reported excellent progress toward elimination of hepatitis C among their populations. Additionally, the Alaska Native Tribal Health Consortium announced the elimination of acute hepatitis B and early-onset of hepatocellular carcinoma as a public health threat among its pediatric population.

All adolescent patients available for follow-up after treatment with Harvoni for chronic hepatitis C genotype 1 achieved sustained virologic response at 12 weeks with no serious adverse events, further supporting its approval in this population.